These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19963387)

  • 21. Animal models of stroke: do they have value for discovering neuroprotective agents?
    Richard Green A; Odergren T; Ashwood T
    Trends Pharmacol Sci; 2003 Aug; 24(8):402-8. PubMed ID: 12915049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia.
    Schomacher M; Müller HD; Sommer C; Schwab S; Schäbitz WR
    Brain Res; 2008 Nov; 1240():213-20. PubMed ID: 18823959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
    Allahtavakoli M; Moloudi R; Arababadi MK; Shamsizadeh A; Javanmardi K
    Brain Res; 2009 May; 1271():121-7. PubMed ID: 19332033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of semiparametric mixed models and simultaneous confidence bands in a cardiovascular safety experiment with longitudinal data.
    Maringwa JT; Geys H; Shkedy Z; Faes C; Molenberghs G; Aerts M; Ammel KV; Teisman A; Bijnens L
    J Biopharm Stat; 2008; 18(6):1043-62. PubMed ID: 18991107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotective therapies: Preclinical reproducibility is only part of the problem.
    Tymianski M
    Sci Transl Med; 2015 Aug; 7(299):299fs32. PubMed ID: 26246165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy: report of the expert workshop "Pre-clinical testing for SMA", Zürich, March 29-30th 2010.
    Willmann R; Dubach J; Chen K;
    Neuromuscul Disord; 2011 Jan; 21(1):74-7. PubMed ID: 21115346
    [No Abstract]   [Full Text] [Related]  

  • 27. Progesterone treatment for experimental stroke: an individual animal meta-analysis.
    Wong R; Renton C; Gibson CL; Murphy SJ; Kendall DA; Bath PM;
    J Cereb Blood Flow Metab; 2013 Sep; 33(9):1362-72. PubMed ID: 23838830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles.
    Samsa GP; Matchar DB
    Stroke; 2001 Mar; 32(3):669-74. PubMed ID: 11239185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Statistical concepts related to negative clinical results].
    Chen W; Zheng GH; Liu JP
    Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):487-90. PubMed ID: 21565133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia.
    Macrae IM
    Br J Pharmacol; 2011 Oct; 164(4):1062-78. PubMed ID: 21457227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.
    Bath PM; Gray LJ; Bath AJ; Buchan A; Miyata T; Green AR;
    Br J Pharmacol; 2009 Aug; 157(7):1157-71. PubMed ID: 19422398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for standards regarding preclinical neuroprotective and restorative drug development.
    Stroke Therapy Academic Industry Roundtable (STAIR)
    Stroke; 1999 Dec; 30(12):2752-8. PubMed ID: 10583007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents.
    Schmidt-Pogoda A; Bonberg N; Koecke MHM; Strecker JK; Wellmann J; Bruckmann NM; Beuker C; Schäbitz WR; Meuth SG; Wiendl H; Minnerup H; Minnerup J
    Ann Neurol; 2020 Jan; 87(1):40-51. PubMed ID: 31714631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guide for calculating and interpreting effect sizes and confidence intervals in intellectual and developmental disability research studies.
    Dunst CJ; Hamby DW
    J Intellect Dev Disabil; 2012 Jun; 37(2):89-99. PubMed ID: 22530580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On effect size.
    Kelley K; Preacher KJ
    Psychol Methods; 2012 Jun; 17(2):137-52. PubMed ID: 22545595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the use of historical control data in pre-clinical safety studies.
    Marringwa JT; Faes C; Aerts M; Geys H; Teuns G; Van Den Poel B; Bijnens L
    J Biopharm Stat; 2007; 17(3):493-509. PubMed ID: 17479396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The seven wonders of China in stroke therapy: fact or illusion?
    Bereczki D
    Stroke; 2007 Nov; 38(11):e142; author reply e143. PubMed ID: 17872478
    [No Abstract]   [Full Text] [Related]  

  • 38. NXY-059 for the treatment of stroke.
    Savitz SI; Fisher M
    N Engl J Med; 2007 Nov; 357(21):2198; author reply 2198-9. PubMed ID: 18032772
    [No Abstract]   [Full Text] [Related]  

  • 39. Organizational Update: NINDS Stroke Research Strategies for Large Vessel Occlusion and Neuroprotection.
    Wright CB; Bosetti F; Janis LS; Koenig JI; Moy CS
    Stroke; 2021 Jan; 52(1):e1-e2. PubMed ID: 33370178
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictions models in acute stroke: potential uses and limitations.
    Dennis M
    Stroke; 2008 Jun; 39(6):1665-6. PubMed ID: 18403744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.